Sponsor Dossier
Organon Pharma
Sponsor Dossier for Organon Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ANTROQUORIL
- Brand: ARCOXIA
- Brand: ATOZET
- Brand: AVANZA
- Brand: CELESTONE
- Brand: CELESTONE-M
- Brand: COZAAR
- Brand: DIPROSONE
- Device (sponsor): JADA System - Intrauterine haemostatic suction catheter
- Device (sponsor): Applicator, vaginal, single use
- Device (sponsor): Hypodermic needle, single-use, sterile
- Device (sponsor): Needle, injector, medication/vaccine
- Device (sponsor): Follicle stimulating hormone pen
About
Organon Pharma is an Australian Private Company with ABN 54637107512, registered in NSW and currently active.
Portfolio
Organon Pharma holds 46 brands on the ARTG, of which 40 are indexable. The portfolio includes 40 brands with Product Information on file, 8 brands with at least one PBS-listed item, 10 brands with PBAC outcome(s) on record, and 3 brands with AusPAR(s) on record. Notable brands include ARCOXIA, AVANZA, COZAAR, ELOCON and ELONVA.
Therapeutic focus
Organon Pharma's portfolio spans the following therapeutic areas: — Cardiology: 12 brands — Neurology: 8 brands — Dermatology: 7 brands — Women's Health: 6 brands — Oncology: 2 brands — Respiratory: 2 brands — Infectious Disease: 2 brands — Reproductive Health: 2 brands — Pain & Anaesthesia: 1 brand — Urology: 1 brand — Musculoskeletal: 1 brand — Endocrinology: 1 brand — Immunology: 1 brand
PBS footprint
Eight brands in Organon Pharma's portfolio hold at least one PBS-listed item, with the latest PBS schedule date touched on 1 May 2026.
Regulatory activity
Organon Pharma's most recent PBAC outcome was dated 1 May 2025 across 10 brands with recorded PBAC outcomes. The most recent AusPAR dates to 20 November 2013 across 3 brands with recorded AusPARs.